**Appendix/Supplements Materials**

**Table 1. Input variables by country for the Markov cohort model**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Australia value** | **UK value** | **Sources** |
| **Proportion of cases diagnosed without screening** |  |  |  |
| Early | 39% | 30% | [1](https://paperpile.com/c/74QRAG/VG3Pb),[2](https://paperpile.com/c/74QRAG/9d3Pm) |
| Mild | 69% | 50% | [1](https://paperpile.com/c/74QRAG/VG3Pb),[2](https://paperpile.com/c/74QRAG/9d3Pm) |
| Moderate | 69% | 50% | [1](https://paperpile.com/c/74QRAG/VG3Pb),[2](https://paperpile.com/c/74QRAG/9d3Pm) |
| Severe | 0% | 0% | Assumption |
| **Transition probabilities** |  |  |  |
| No disease to early disease stage | **\*** | **\*** |  |
| Early disease stage -> mild | **\*** | **\*** |  |
| Mild to moderate | 85% | 85% | [3](https://paperpile.com/c/74QRAG/uRK71) |
| Moderate to severe | 30% | 30% | [3](https://paperpile.com/c/74QRAG/uRK71) |
| **Treatment relative risk** | 0.44 | 0.44 | [4](https://paperpile.com/c/74QRAG/G32p0) |
| **Utility multipliers** |  |  |  |
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | Assumption |
| Mild | 0.79 | 0.79 | [5](https://paperpile.com/c/74QRAG/CzQ1q) |
| Moderate | 0.64 | 0.64 | [5](https://paperpile.com/c/74QRAG/CzQ1q) |
| Severe | 0.26 | 0.26 | [6](https://paperpile.com/c/74QRAG/9kteE) |
| **Costs (AUD and GBP respectively)** |  |  |  |
| Genetic screening test per patient | 350.00 | 175.00 | [7,8](https://paperpile.com/c/74QRAG/4d4A+xgMi) |
| Annual screening costs per patient | 34.43 | 51.28 | Calculated from references[9](https://paperpile.com/c/74QRAG/Xyyey) [10](https://paperpile.com/c/74QRAG/apIsU); |
| Annual POAG treatment costs per patient | 2,012.80 | 563.83 | Calculated from references[11](https://paperpile.com/c/74QRAG/Ntb0)\*\* |
| Annual depression treatment per patient | 1,405.89 | 2,930.41 | Calculated from references[12,13](https://paperpile.com/c/74QRAG/YzAYa+LHjyd) |
| Annual residential aged care facility costs per resident | 66,540.52 | 47,850.90 | [14](https://paperpile.com/c/74QRAG/1qrle), [15](https://paperpile.com/c/74QRAG/394DU) |
| Fall costs per event | 13,466.04 | 2,806.00 | Calculated from references[16](https://paperpile.com/c/74QRAG/jGoEo),[17](https://paperpile.com/c/74QRAG/yauxy) |
| **POAG cost weighting by disease stage** |  |  |  |
| Early disease stage | 0.934 | 0.934 | [18](https://paperpile.com/c/74QRAG/b3HnL) |
| Mild | 1.116 | 1.116 | [18](https://paperpile.com/c/74QRAG/b3HnL) |
| Moderate | 1.21 | 1.21 | [18](https://paperpile.com/c/74QRAG/b3HnL) |
| Severe | 1.559 | 1.559 | [18](https://paperpile.com/c/74QRAG/b3HnL) |
| **Relative risk of disease states - Mortality** |  |  |  |
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | [3](https://paperpile.com/c/74QRAG/uRK71) |
| Mild | 1.67 | 1.67 | [3](https://paperpile.com/c/74QRAG/uRK71) |
| Moderate | 2.34 | 2.34 | [3](https://paperpile.com/c/74QRAG/uRK71) |
| Severe | 3.01 | 3.01 | [3](https://paperpile.com/c/74QRAG/uRK71) |
| **Relative risk of disease states - Depression** |  |  |  |
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Mild | 1 | 1 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Moderate | 3.5 | 3.5 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Severe | 3.5 | 3.5 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| **Relative risk of disease states - Fall events** |  |  |  |
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Mild | 1.25 | 1.25 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Moderate | 1.49 | 1.49 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Severe | 1.74 | 1.74 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| **Relative risk of aged care facility admission** |  |  |  |
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Mild | 1 | 1 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Moderate | 1.8 | 1.8 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| Severe | 1.8 | 1.8 | [19](https://paperpile.com/c/74QRAG/8uX5u) |
| **Mortality rates by age** |  |  |  |
| 40 | 0.11% | 0.12% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 41 | 0.12% | 0.13% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 42 | 0.13% | 0.14% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 43 | 0.14% | 0.15% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 44 | 0.15% | 0.16% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 45 | 0.16% | 0.17% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 46 | 0.17% | 0.19% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 47 | 0.19% | 0.20% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 48 | 0.20% | 0.22% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 49 | 0.22% | 0.23% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 50 | 0.23% | 0.25% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 51 | 0.25% | 0.27% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 52 | 0.28% | 0.30% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 53 | 0.30% | 0.32% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 54 | 0.33% | 0.35% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 55 | 0.35% | 0.38% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 56 | 0.38% | 0.42% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 57 | 0.41% | 0.46% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 58 | 0.45% | 0.51% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 59 | 0.49% | 0.56% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 60 | 0.53% | 0.61% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 61 | 0.58% | 0.67% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 62 | 0.63% | 0.74% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 63 | 0.67% | 0.80% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 64 | 0.73% | 0.88% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 65 | 0.79% | 0.95% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 66 | 0.86% | 1.04% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 67 | 0.95% | 1.14% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 68 | 1.04% | 1.25% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 69 | 1.15% | 1.37% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 70 | 1.27% | 1.51% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 71 | 1.41% | 1.67% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 72 | 1.56% | 1.86% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 73 | 1.74% | 2.06% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 74 | 1.93% | 2.30% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 75 | 2.15% | 2.57% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 76 | 2.39% | 2.87% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 77 | 2.69% | 3.21% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 78 | 3.03% | 3.59% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 79 | 3.41% | 4.02% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 80 | 3.86% | 4.50% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 81 | 4.37% | 5.06% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 82 | 4.96% | 5.70% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 83 | 5.61% | 6.44% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 84 | 6.40% | 7.30% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 85 | 7.28% | 8.26% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 86 | 8.26% | 9.35% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 87 | 9.39% | 10.55% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 88 | 10.63% | 11.87% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 89 | 12.02% | 13.31% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 90 | 13.52% | 14.88% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 91 | 15.12% | 16.57% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 92 | 16.80% | 18.39% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 93 | 18.55% | 20.30% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 94 | 20.35% | 22.30% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 95 | 21.50% | 24.38% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 96 | 23.21% | 26.59% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 97 | 24.80% | 29.00% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 98 | 27.02% | 31.58% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 99 | 30.14% | 34.26% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| 100 | 33.40% | 37.01% | [20](https://paperpile.com/c/74QRAG/RzvtK),[21](https://paperpile.com/c/74QRAG/rK4lW) |
| **\***See Table 2.  \*\*See Method section subtitled *Cost* | | | |

**Table 2. Input variables by age range for the Markov cohort model**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Country** | **40-49** | **50-59** | **60-69** | **70-79** | **80+** | **Source** |
| **Initial state at model beginning** |  |  |  |  |  |  |  |
| No disease | Australia | 99.94% | 98.99% | 98.84% | 97.97% | 0.98% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| Early | Australia | 0.06% | 0.95% | 0.94% | 1.70% | 1.25% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| Mild | Australia | 0.00% | 0.06% | 0.03% | 0.04% | 0.15% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| Moderate | Australia | 0.00% | 0.00% | 0.20% | 0.29% | 1.05% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| Severe | Australia | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| No disease | UK | 99.71% | 99.46% | 98.99% | 98.04% | 96.24% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| Early | UK | 0.29% | 0.48% | 0.46% | 0.81% | 1.15% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| Mild | UK | 0.00% | 0.07% | 0.07% | 0.14% | 0.33% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| Moderate | UK | 0.00% | 0.00% | 0.49% | 1.01% | 2.28% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| Severe | UK | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| **Annual transition rates** |  |  |  |  |  |  |  |
| No disease to Early | Australia | 0.02% | 0.28% | 0.28% | 0.29% | 0.29% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| Early to Mild | Australia | 0.00% | 3.80% | 9.80% | 10.00% | 17.00% | Calculated from reference[22](https://paperpile.com/c/74QRAG/WMMlV) |
| No disease to Early | UK | 0.03% | 0.14% | 0.14% | 0.22% | 0.90% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| Early to Mild | UK | 0.00% | 3.50% | 11.40% | 11.40% | 36.50% | Calculated from reference[23](https://paperpile.com/c/74QRAG/K4nKI) |
| **Associated 'cost states' by age** |  |  |  |  |  |  |  |
| Depression | Australia | 7.10% | 4.20% | 4.20% | 2.80% | 2.80% | [24](https://paperpile.com/c/74QRAG/gNjGU) |
| Falls | Australia | 0.00% | 0.00% | 1.00% | 2.00% | 9.00% | [25](https://paperpile.com/c/74QRAG/UVa2p) |
| Aged Care Facility Admission | Australia | 0.00% | 0.10% | 0.40% | 1.80% | 17.50% | [26](https://paperpile.com/c/74QRAG/IOvNK) |
| Depression | UK | 43.00% | 44.50% | 32.50% | 17.00% | 13.00% | [27](https://paperpile.com/c/74QRAG/iOXBY) |
| Falls | UK | 0.26% | 0.39% | 0.69% | 1.58% | 6.72% | [28](https://paperpile.com/c/74QRAG/Mwd0N) |
| Aged Care Facility Admission | UK | 0.00% | 0.00% | 0.32% | 1.73% | 8.26% | [29](https://paperpile.com/c/74QRAG/yvEx2) |
| **Utility by age** |  |  |  |  |  |  |  |
| - | Australia | 0.91 | 0.89 | 0.88 | 0.85 | 0.83 | [30](https://paperpile.com/c/74QRAG/7r87k) |
| - | UK | 0.88 | 0.83 | 0.79 | 0.76 | 0.73 | [31](https://paperpile.com/c/74QRAG/dbCBY) |
| *Insert notes here as relevant* | | | | | | | |

**Table 3. Comparison of running model for lifetime of participants vs. for 30 years**

|  |  |  |
| --- | --- | --- |
|  | ICER at lifetime model length | ICER at 30 years |
| Aus ($) | 34252 | 34852 |
| UK (£) | 24783 | 26213 |

**References**

1 [Keel S, Xie J, Foreman J, *et al.* Prevalence of glaucoma in the Australian National Eye Health Survey. *Br J Ophthalmol* 2019; **103**: 191–5.](http://paperpile.com/b/74QRAG/VG3Pb)

2 [Reidy A, Minassian DC, Vafidis G, *et al.* Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. *BMJ* 1998; **316**. DOI:](http://paperpile.com/b/74QRAG/9d3Pm)[10.1136/bmj.316.7145.1643](http://dx.doi.org/10.1136/bmj.316.7145.1643)[.](http://paperpile.com/b/74QRAG/9d3Pm)

3 Centre for Eye Research Australia and Access Economics Pty Limited. [Tunnel Vision-The Economic Impact Of Primary Open Angle Glaucoma.](http://paperpile.com/b/vnemJN/QJ9F6) Centre for Eye Research Australia, University of Melbourne, Australia, February 2008. http://www.icoph.org/dynamic/attachments/resources/cera\_tunnelvision.pdf [(accessed Oct 27, 2020)](http://paperpile.com/b/vnemJN/QJ9F6)[.](http://paperpile.com/b/74QRAG/uRK71)

4 [Garway-Heath DF, Crabb DP, Bunce C, *et al.* Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet* 2015; **385**: 1295–304.](http://paperpile.com/b/74QRAG/G32p0)

5 [Burr JM, Kilonzo M, Vale L, Ryan M. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. *Optom Vis Sci* 2007; **84**. DOI:](http://paperpile.com/b/74QRAG/CzQ1q)[10.1097/OPX.0b013e3181339f30](http://dx.doi.org/10.1097/OPX.0b013e3181339f30)[.](http://paperpile.com/b/74QRAG/CzQ1q)

6 [Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. *Br J Ophthalmol* 2001; **85**: 327–31.](http://paperpile.com/b/74QRAG/9kteE)

7 [NHS. Screening for breast cancer genes ‘is cost-effective’. NHS website](http://paperpile.com/b/vnemJN/uQZCb)<https://www.nhs.uk/news/cancer/screening-breast-cancer-genes-cost-effective/> [(accessed Nov 15, 2020).](http://paperpile.com/b/74QRAG/4d4A)

8 Sonic Genetics[.](http://paperpile.com/b/kj93pd/zb5F) Breast cancer focused gene panel. Sonic Genetics website, 2020 [https://www.sonicgenetics.com.au/our-tests/all-tests/breast-cancer-focused-gene-panel](http://paperpile.com/b/vnemJN/Twh78) [(accessed Nov 15, 2020).](http://paperpile.com/b/74QRAG/xgMi)

9 Department of Health, Australian Government. Medicare Benefits Schedule -[Item 10910.](http://paperpile.com/b/kj93pd/7BWU) Commonwealth of Australia MBS online. <http://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&qt=ItemID&q=10910> [(accessed Nov 15, 2020).](http://paperpile.com/b/74QRAG/Xyyey)

10 [Violato M, Dakin H, Chakravarthy U, *et al.* Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. *BMJ Open* 2016; **6**: e011121.](http://paperpile.com/b/74QRAG/apIsU)

11 [Rahman MQ, Beard SM, Discombe R, Sharma R, Montgomery DM. Direct healthcare costs of glaucoma treatment. *Br J Ophthalmol* 2013; **97**. DOI:](http://paperpile.com/b/74QRAG/Ntb0)[10.1136/bjophthalmol-2012-302525](http://dx.doi.org/10.1136/bjophthalmol-2012-302525)[.](http://paperpile.com/b/74QRAG/Ntb0)

12 McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price: the cost of mental health care in England to 2026. King’s Fund, London, 2008. <https://www.kingsfund.org.uk/sites/default/files/Paying-the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-Fund-May-2008_0.pdf> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/YzAYa)

13 Australian Institute of Health and welfare. [Disease expenditure in Australia.](http://paperpile.com/b/kj93pd/IdkL) Australian Government; last updated: 13 Jun 2019. <https://www.aihw.gov.au/reports/health-welfare-expenditure/disease-expenditure-australia/contents/summary> [(accessed Nov 21, 2020).](http://paperpile.com/b/74QRAG/LHjyd)

14 Department of Health, Australian Institute of Health and welfare. [Aged care service list: 30 June 2019.](http://paperpile.com/b/kj93pd/UlXL) Australian Government; released online Sep 2019. <https://www.gen-agedcaredata.gov.au/Resources/Access-data/2019/September/Aged-care-service-list-30-June-2019> [(accessed Oct 2, 2020).](http://paperpile.com/b/74QRAG/1qrle)

15 Care Markets and LaingBuisson. Annual Survey Of UK Local Authority Usual Costs 2017/2018. LaingBuisson website; released July 2017<https://www.laingbuisson.com/wp-content/uploads/sites/3/2017/07/CareMarkets_UsualCosts_20172018.pdf> [(accessed Nov 5, 2020).](http://paperpile.com/b/74QRAG/394DU)

16 Australian Institute of Health and welfare 2019. Admitted patient care 2017-18: Australian hospital statistics. Health services series no. 90. Cat. no HSE 225. Canberra: AIHW <https://www.aihw.gov.au/getmedia/df0abd15-5dd8-4a56-94fa-c9ab68690e18/aihw-hse-225.pdf.aspx?inline=true> [(accessed Nov 5, 2020).](http://paperpile.com/b/74QRAG/jGoEo)

17 McGinley P, Ansari E, Sandhu H & Dixon T 2020. The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK, Journal of Medical Economics, 23:1, 106-112, DOI: [10.1080/13696998.2019.1646262](https://doi.org/10.1080/13696998.2019.1646262)

18 [Varma R, Lee PP, Goldberg I, Kotak S. An Assessment of the Health and Economic Burdens of Glaucoma. *Am J Ophthalmol* 2011; **152**: 515.](http://paperpile.com/b/74QRAG/b3HnL)

19 [Dirani M, Crowston JG, Taylor PS, *et al.* Economic impact of primary open-angle glaucoma in Australia. *Clin Experiment Ophthalmol* 2011; **39**. DOI:](http://paperpile.com/b/74QRAG/8uX5u)[10.1111/j.1442-9071.2011.02530.x](http://dx.doi.org/10.1111/j.1442-9071.2011.02530.x)[.](http://paperpile.com/b/74QRAG/8uX5u)

20 Australian Bureau of Statistics[. Deaths, Year of occurrence, Age at death, Age-specific death rates, Sex, States, Territories and Australia.](http://paperpile.com/b/vnemJN/NU1Gz) [ABS, Commonwealth of Australia](http://paperpile.com/b/kj93pd/Ecp4), [2020.](http://paperpile.com/b/vnemJN/NU1Gz)<http://stat.data.abs.gov.au/Index.aspx?DataSetCode=DEATHS_AGESPECIFIC_OCCURENCEYEAR> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/RzvtK)

21 [Morgan E. National life tables: UK. Office for National Statistics; publication date 24 Sept 2020.](http://paperpile.com/b/74QRAG/rK4lW) <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables> [(accessed Nov 5, 2020).](http://paperpile.com/b/74QRAG/rK4lW)

22 [Keel S, Xie J, Foreman J, *et al.* Prevalence of glaucoma in the Australian National Eye Health Survey. *Br J Ophthalmol* 2019; **103**: 191–5.](http://paperpile.com/b/74QRAG/WMMlV)

23 [Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in Primary Open-Angle Glaucoma Prevalence by Age, Gender, and Race: A Bayesian Meta-Analysis. Investigative Opthalmology & Visual Science. 2006; **47**: 4254.](http://paperpile.com/b/74QRAG/K4nKI)

24 Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing: Summary of Results[.](http://paperpile.com/b/shUR8v/6wT57) ABS, Commonwealth of Australia; released online 23 Oct 2008. <https://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/6AE6DA447F985FC2CA2574EA00122BD6/$File/National%20Survey%20of%20Mental%20Health%20and%20Wellbeing%20Summary%20of%20Results.pdf> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/gNjGU)

25 Australian Institute of Health and Welfare. [Trends in hospitalised injury due to falls in older people 2007–08 to 2016–17. AIHW Australian Government](http://paperpile.com/b/kj93pd/yG2b); release date 19 Sep 2019 <https://www.aihw.gov.au/reports/injury/trends-in-hospitalised-injury-due-to-falls/contents/table-of-contents> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/UVa2p)

26 GEN, Australian Institute of Health and Welfare. GEN data: admission into age care[.](http://paperpile.com/b/74QRAG/IOvNK) Australian Government; release Aug 2020 <https://gen-agedcaredata.gov.au/> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/IOvNK)

27 [Mental Health Foundation 2016. Fundamental Facts About Mental Health 2016. Mental Health Foundation: London](http://paperpile.com/b/74QRAG/iOXBY) <https://www.mentalhealth.org.uk/sites/default/files/fundamental-facts-about-mental-health-2016.pdf> [(accessed Oct 15, 2020).](http://paperpile.com/b/74QRAG/iOXBY)

28 NHS. [Hospital Admitted Patient Care Activity, 2017-18: National statistics. NHS Digital; publication date 20 Sep 2018.](http://paperpile.com/b/74QRAG/Mwd0N) <https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2017-18> [(accessed Nov 21, 2020).](http://paperpile.com/b/74QRAG/Mwd0N)

29 [Smith M. Changes in the Older Resident Care Home Population between 2001 and 2011.Office for National](http://paperpile.com/b/74QRAG/yvEx2) [Statistics](http://paperpile.com/b/74QRAG/rK4lW)[; published online 1 Aug 2014.](http://paperpile.com/b/74QRAG/yvEx2) <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/ageing/articles/changesintheolderresidentcarehomepopulationbetween2001and2011/2014-08-01> [(accessed Oct 14, 2020).](http://paperpile.com/b/74QRAG/yvEx2)

30 [McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. *Health Qual Life Outcomes* 2016; **14**: 1–12.](http://paperpile.com/b/74QRAG/7r87k)

31 [Kind P, Hardman G, Macran S 1999. UK Population Norms for EQ-5D. The University of York, Centre for Health Economics, University of York, York.](http://paperpile.com/b/74QRAG/dbCBY) <https://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf> [(accessed Oct 14, 2020).](http://paperpile.com/b/74QRAG/dbCBY)